Resources

In part 8, the conclusion of this Exclusive Interview, Dr. Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the reward of his work and making time for patients.

In this week's Homerun Slides, Dr. Stanley Schwartz updates his lecture on a unifying pathophysiologic approach to the complications of diabetes in the context of the beta-cell classification of diabetes with a framework for understanding diabetes.

Combined dietary intervention and exercise: The available information on the role of combined lifestyle interventions (hypocaloric diets plus exercise) in patients with NAFLD is much more extensive, with several randomized, controlled trials showing significant benefit with this comprehensive approach. Again, the overall reduction in liver fat reported in most of these trials has been strongly correlated with the amount of weight loss.

Poll finds less than half of health care professionals aware of newest drug up for FDA approval.

How can health care practitioners play a more prominent role in helping patients to take prescribed medications?

The first study to examine overtreatment and deintensification in a Medicare population with diabetes.

Study reports Vitamin D supplementation may improve HbA1c and lower cholesterol.

Would you be interested in learning about a program that can determine the best individual treatments for patients with type 2, based on what the patient can afford using their insurance? Follow the link to see how your colleagues responded.

A 47-year-old patient returns for a follow-up visit. He currently takes metformin 2000 mg daily, but is not achieving his glycemic target of A1C <7 %. His current A1C is 8.0%. You would like to add a second medication to his regimen, however, he voices concern that he is no longer covered by any health insurance and is worried about how to pay for his medications. Taking his concern into consideration, what drug would you add to metformin? A. DPP-4 inhibitor B. Thiazolidine C. Sulfonylurea D. Meglitinide E. SGLT2 Inhibitor F. GLP-1 Agonists Follow the link to see the answer.

Richard E. Pratley, MD serves as the Medical Director of the Florida Hospital Diabetes Institute. He is also a senior scientist at the Florida Hospital /Sanford- Burnham Translational Research Institute for Metabolism and Diabetes and a professor at the Sanford-Burnham Medical Research Institute at Lake Nona.